An international double-blind placebo-controlled trial of lamivudine in 286 children with chronic hepatitis B (CHB)

Akut viral hepatit B

“…195 çocukta 3 mg/kg ile 52 hafta süre ile yap›lan tedavide HBeAg serokonversiyonu tedavi alanlarda %23, tedavi almayanlarda %13 olarak saptanm›flt›r. 2,[22][23][24] Lamivüdin oral al›nd›¤›nda iyi emilir, çocuklarda bi-yoyararl›l›¤› %68'dir. Çocuklarda önerilen dozu 3 mg/kg d›r.…”

501 Lamivudine therapy in children with chronic hepatitis B

“…Spontaneous seroconversion of HBeAg/HBeAb during the course of chronic hepatitis B is observed only in less than 10% of children, and total recovery with the elimination of all virus antigens and the presence of anti-HBs occurs in approximately 2% of cases [4] . In recent years lamivudine treatment for chronic hepatitis B has been recommended for patients who fail to respond to IFN-α therapy or have contraindications for this therapy [5] . However clinical data concerning nucleotide analogue treatment for CHB children are lacking.…”

Tolerance of interferon‐alpha therapy in children with chronic hepatitis B

“…Until now, interferon alpha (INF‐α) therapy has been the most recommended treatment for chronic hepatitis B in children. In recent years lamivudine treatment for chronic hepatitis B in children has been especially recommended for patients who did not respond to IFN‐α therapy, or who have contraindications to this therapy 9 . The positive effect of IFN‐α therapy (inhibition of virus replication) is observed in 30−40% of adult patients 10 .…”